For the Inventor, By the Inventor

Enter assignee name

Philogen S.p.a.

USPTO Granted Patents = 50

CIPO Patents = 77

EPO Patents = 33

Trademarks = 5

Forward Citations = 142

Loading Chart...

Loading Chart...

120 inventors (with patents filed for the assignee):

Dario Neri (22 out of 40 patents)

Kathrin Schwager (9 out of 9 patents)

Giovanni Neri (8 out of 9 patents)

4. Sarah Wulhfard (8 out of 8 patents)

5. Alessandra Villa (7 out of 7 patents)

6. Luciano Zardi (7 out of 7 patents)

7. Barbara Carnemolla (6 out of 6 patents)

8. Manuela Kaspar (5 out of 6 patents)

9. Eveline Trachsel (5 out of 5 patents)

10. Roberto De Luca (4 out of 4 patents)

11. Francesca Pretto (4 out of 4 patents)

12. Jascha-Nikolai Rybak (4 out of 4 patents)

13. Christoph Rosli (4 out of 4 patents)

14. Laura Gualandi (3 out of 3 patents)

15. Gregory Paul Winter (3 out of 75 patents)

Core Competencies:

TNF-Alpha Immunoconjugate

IL-12 Compositions

Antibody Compositions

Vascular Endothelial Growth Factor

Immunocytokine Therapy

Anti-Fibroblast Activation Protein

Neoplastic Disease Treatment

Angiogenesis Treatment

Tumor Vasculature Targeting

Tenascin-C Antibodies

Inflammatory Bowel Disease

Rheumatoid Arthritis Antigens

50 patents: Sort by Forward Citations

1. 12377161 - TNF-alpha immunoconjugate therapy for the treatment of brain tumors (2025-08-05),

2. 12173044 - EDB targeting IL-12 compositions (2024-12-24),

3. 12023381 - Antibody compositions (2024-07-02),

4. 11872288 - TNF-alpha immunoconjugate therapy for the treatment of brain tumors (2024-01-16),

5. 11629199 - Antibodies to tumour antigens (2023-04-18),

6. 11390666 - Vascular endothelial growth factor/anti-fibronectin antibody fusion proteins (2022-07-19),

7. 11351257 - Antibody compositions (2022-06-07),

8. 11274133 - IL2 and TNF immunoconjugates (2022-03-15),

9. 11103592 - IL2 and TNF mutant immunoconjugates (2021-08-31),

10. 10906963 - Non-glycosylated anti-tenascin antibody (2021-02-02),

11. 10858411 - IL22 immunoconjugates (2020-12-08),

12. 10647760 - Antibodies for treatment and diagnosis of inflammatory bowel disease (2020-05-12),

13. 10519246 - Anti-fibroblast activation protein (FAP) antibodies for treatment and diagnosis (2019-12-31),

14. 10385121 - Antigen associated with rheumatoid arthritis (2019-08-20),

15. 10344079 - Methods of treating a neoplastic disease (2019-07-09),

PhiloGen S.p.A. is a biotechnology company that specializes in the discovery, development, and production of innovative immunotherapeutic drugs. With a focus on cancer treatment, PhiloGen leverages its expertise in antibody engineering and peptide research to create targeted therapies. Through strategic collaborations and cutting-edge technology, the company aims to improve patient outcomes and contribute to advancements in the field of immunology.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 2 2025

50 Patents

#1 in

#173 in

#13,566 in the World

Philogen S.p.a.

Forward Citations = 142

120 inventors:

Dario Neri (22 out of 40 patents)

Kathrin Schwager (9 out of 9 patents)

Giovanni Neri (8 out of 9 patents)

4. Sarah Wulhfard (8 out of 8 patents)

5. Alessandra Villa (7 out of 7 patents)

Please report any incorrect information to support@idiyas.com

Loading…